Clobetasol propionate lichen sclerosus

Like other topical corticosteroids, clobetasol propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor , arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

The following local adverse reactions are reported infrequently when topical corticosteroids are used as recommended. These reactions are listed in an approximately decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, manifestations of Cushing syndrome, hyperglycemia, and glucosuria in some patients. In rare instances, treatment (or withdrawal of treatment) of psoriasis with corticosteroids is thought to have exacerbated the disease or provoked the pustular form of the disease, so careful patient supervision is recommended.

"Studies in the rat following oral administration at dosage levels up to 50 mcg/kg per day revealed that the females exhibited an increase in the number of resorbed embryos and a decrease in the number of living fetuses at the highest dose. Pregnancy: Teratogenic Effects (., possibility of causing abnormalities in fetuses): Pregnancy Category C: Clobetasol propionate has not been tested for teratogenicity when applied topically; however, it is absorbed percutaneously, and when administered subcutaneously it was a significant teratogen in both the rabbit and mouse. Clobetasol propionate has greater teratogenic potential than steroids that are less are no adequate and well-controlled studies of the teratogenic effects of clobetasol propionate in pregnant women. Temovate Cream and Ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."

Temovate Cream or Ointment is applied topically (on the skin) to the affected areas twice daily. Treatment should be limited to 2 consecutive weeks and amounts greater than 50 g/week should not be used. Temovate may interact with corticosteroids taken by mouth or drugs that lower the immune system . Tell your doctor about all medications you are taking. During pregnancy, Temovate should be used only when prescribed. It is not known whether this drug passes into breast milk when applied to the skin. Similar medications pass into breast milk when taken by mouth. Consult your doctor before breastfeeding.

Clobetasol propionate lichen sclerosus

clobetasol propionate lichen sclerosus

Temovate Cream or Ointment is applied topically (on the skin) to the affected areas twice daily. Treatment should be limited to 2 consecutive weeks and amounts greater than 50 g/week should not be used. Temovate may interact with corticosteroids taken by mouth or drugs that lower the immune system . Tell your doctor about all medications you are taking. During pregnancy, Temovate should be used only when prescribed. It is not known whether this drug passes into breast milk when applied to the skin. Similar medications pass into breast milk when taken by mouth. Consult your doctor before breastfeeding.

Media:

clobetasol propionate lichen sclerosusclobetasol propionate lichen sclerosusclobetasol propionate lichen sclerosusclobetasol propionate lichen sclerosusclobetasol propionate lichen sclerosus

http://buy-steroids.org